skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis

Review

(1482) Views  (501) Full article downloads

Authors: Eliana Krulig, Kenneth B Gordon

Published Date July 2010 Volume 2010:5 Pages 11 - 22
DOI: http://dx.doi.org/10.2147/CE.S5994

Eliana Krulig, Kenneth B Gordon

NorthShore University HealthSystem, University of Chicago, Pritzker School of Medicine, Skokie, IL, USA

Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated the essential role of specific cytokines in the development of this complex disease, including TNF-, interleukin-23 (IL-23), and potentially, IL-22. These are all part of a newly defined autoimmune pathway directed by specialized T cells called Th17 helper T cells. Ustekinumab is a fully human monoclonal antibody that targets IL-12 and IL-23, thus targeting both Th1 and Th17 arms of immunity. It has a promising efficacy and safety profile that not only represents a valuable treatment alternative, but also a continuation in our constantly evolving understanding of this disorder.
Aims: To review the emerging evidence supporting the use of ustekinumab in the management of moderate to severe plaque psoriasis.
Evidence review: There is clear evidence that ustekinumab is effective in the treatment of moderate to severe psoriasis. Phase III trials (PHOENIX 1 and 2) demonstrated a statistically significant difference between Psoriasis Area and Severity Index (PASI) 75 responses achieved by patients receiving ustekinumab, given as a 45 mg or 90 mg subcutaneous injection every 12 weeks, than their placebo counterparts. Treatment with this novel agent resulted in a rapid onset of action, with over 60% of treated patients attaining Physician’s Global Assessment (PGA) scores of “cleared” or “minimal” by week 12. Quality of life assessments paralleled clinical improvements.
Clinical potential: Ustekinumab is an effective and efficient therapeutic option for patients with moderate to severe psoriasis. Although further studies are required to establish ustekinumab’s place in the therapy of psoriasis, with its convenient dosing schedule and rapid onset of action, this drug could provide a great addition to the current therapeutic armamentarium available for psoriatic patients.

Keywords: ustekinumab, psoriasis, biologics, interleukin-12 (IL-12), interleukin-23 (IL-23), IL-12/23, evidence






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Health literacy and health seeking behavior among older men in a middle-income nation
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation
Investigational new drugs in the treatment of inflammatory bowel disease: a review
Editorial
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University